A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2019-08-23
Target enrollment:
Participant gender:
Summary
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma.
SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment
2, SGN-CD48A was given every 3 weeks.